Emerging role of extracellular nucleotides and adenosine in multiple sclerosis

Purinergic Signalling

Volumn 7, Issue 4, 2011, Pages 393-402

  Cieślak, Marek ^a   Kukulski, Filip ^b   Komoszynski M ^c  

^a WSZ Hospital   (Poland)

^b LAVAL UNIVERSITY   (Canada)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Autoimmune encephalomyelitis; Demyelination; Neuroinflammation; P1 receptor; P2 receptor

Indexed keywords

EID: 81955168044     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-011-9250-y     Document Type: Review

References (106)

1. Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G, Filippi M (2002) Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol 1(8): 499-509.
2. Siffrin V, Vogt J, Radbruch H, Nitsch R, Zipp F (2010) Multiple sclerosis-candidate mechanisms underlying CNS atrophy. Trends Neurosci 33(4): 202-210. doi: 10. 1016/j. tins. 2010. 01. 002.
3. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47(6): 707-717.
4. Trapp BD, Nave KA (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31: 247-269. doi: 10. 1146/annurev. neuro. 30. 051606. 094313.
5. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132(Pt 5): 1175-1189. doi: 10. 1093/brain/awp070.
6. Di Virgilio F (2007) Purinergic signalling in the immune system. A brief update. Purinergic Signal 3(1-2): 1-3. doi: 10. 1007/s11302-006-9048-5.
7. Sperlagh B, Illes P (2007) Purinergic modulation of microglial cell activation. Purinergic Signal 3(1-2): 117-127. doi: 10. 1007/s11302-006-9043-x.
8. Link H, Huang YM (2006) Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 180(1-2): 17-28. doi: 10. 1016/j. jneuroim. 2006. 07. 006.
9. Di Virgilio F, Ceruti S, Bramanti P, Abbracchio MP (2009) Purinergic signalling in inflammation of the central nervous system. Trends Neurosci 32(2): 79-87. doi: 10. 1016/j. tins. 2008. 11. 003.
10. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA (2006) International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58(3): 281-341. doi: 10. 1124/pr. 58. 3. 3.
11. Gabel CA (2007) P2 purinergic receptor modulation of cytokine production. Purinergic Signal 3(1-2): 27-38. doi: 10. 1007/s11302-006-9034-y.
12. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC (2006) Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112(2): 358-404. doi: 10. 1016/j. pharmthera. 2005. 04. 013.
13. Jacobson KA, Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5(3): 247-264. doi: 10. 1038/nrd1983.
14. Robson SC, Sévigny J, Zimmermann H (2006) The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2(2): 409-430. doi: 10. 1007/s11302-006-9003-5.
15. Kukulski FLS, Sévigny J (2011) Impact of ectoenzymes on P2 and P1 signaling. Adv Pharmacol 61: 263-299.
16. Narcisse L, Scemes E, Zhao Y, Lee SC, Brosnan CF (2005) The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes. Glia 49(2): 245-258. doi: 10. 1002/glia. 20110.
17. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Banati RR, Anand P (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6: 12. doi: 10. 1186/1471-2377-6-12.
18. Cotrina ML, Nedergaard M (2009) Physiological and pathological functions of P2X7 receptor in the spinal cord. Purinergic Signal 5(2): 223-232. doi: 10. 1007/s11302-009-9138-2.
19. Lister MF, Sharkey J, Sawatzky DA, Hodgkiss JP, Davidson DJ, Rossi AG, Finlayson K (2007) The role of the purinergic P2X7 receptor in inflammation. J Inflamm (Lond) 4: 5. doi: 10. 1186/1476-9255-4-5.
20. Matute C, Torre I, Perez-Cerda F, Perez-Samartin A, Alberdi E, Etxebarria E, Arranz AM, Ravid R, Rodriguez-Antiguedad A, Sanchez-Gomez M, Domercq M (2007) P2X7 receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 27(35): 9525-9533. doi: 10. 1523/JNEUROSCI. 0579-07. 2007.
21. Grygorowicz T, Struzynska L, Sulkowski G, Chalimoniuk M, Sulejczak D (2010) Temporal expression of P2X7 purinergic receptor during the course of experimental autoimmune encephalomyelitis. Neurochem Int 57(7): 823-829. doi: 10. 1016/j. neuint. 2010. 08. 021.
22. Grygorowicz T, Sulejczak D, Struzynska L (2011) Expression of purinergic P2X7 receptor in rat brain during the symptomatic phase of experimental autoimmune encephalomyelitis and after recovery of neurological deficits. Acta Neurobiol Exp (Wars) 71(1): 65-73.
23. Carroll WA, Donnelly-Roberts D, Jarvis MF (2009) Selective P2X7 receptor antagonists for chronic inflammation and pain. Purinergic Signal 5(1): 63-73. doi: 10. 1007/s11302-008-9110-6.
24. Skaper SD, Debetto P, Giusti P (2010) The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J 24(2): 337-345. doi: 10. 1096/fj. 09-138883.
25. Erb L, Liao Z, Seye CI, Weisman GA (2006) P2 receptors: intracellular signaling. Pflugers Arch 452(5): 552-562. doi: 10. 1007/s00424-006-0069-2.
26. Hughes JP, Hatcher JP, Chessell IP (2007) The role of P2X7 in pain and inflammation. Purinergic Signal 3(1-2): 163-169. doi: 10. 1007/s11302-006-9031-1.
27. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A (2001) Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 15(5): 825-835.
28. Bianco F, Pravettoni E, Colombo A, Schenk U, Moller T, Matteoli M, Verderio C (2005) Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J Immunol 174(11): 7268-7277.
29. Pizzirani C, Ferrari D, Chiozzi P, Adinolfi E, Sandona D, Savaglio E, Di Virgilio F (2007) Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells. Blood 109(9): 3856-3864. doi: 10. 1182/blood-2005-06-031377.
30. Bianco F, Perrotta C, Novellino L, Francolini M, Riganti L, Menna E, Saglietti L, Schuchman EH, Furlan R, Clementi E, Matteoli M, Verderio C (2009) Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J 28(8): 1043-1054. doi: 10. 1038/emboj. 2009. 45.
31. 1 receptor-evoked glutamate exocytosis from astrocytes: control by tumor necrosis factor-alpha and prostaglandins. J Biol Chem 281(41): 30684-30696. doi: 10. 1074/jbc. M606429200.
32. Trotti D, Rossi D, Gjesdal O, Levy LM, Racagni G, Danbolt NC, Volterra A (1996) Peroxynitrite inhibits glutamate transporter subtypes. J Biol Chem 271(11): 5976-5979.
33. Mazzola S, Lira MG, Benedetti MD, Salviati A, Ottaviani S, Malerba G, Ortombina M, Pignatti PF (2007) COX-2 promoter region polymorphisms in multiple sclerosis: lack of association of -765G & C with disease risk. Int J Immunogenet 34(2): 71-74. doi: 10. 1111/j. 1744-313X. 2007. 00675. x.
34. Duan S, Anderson CM, Keung EC, Chen Y, Swanson RA (2003) P2X7 receptor-mediated release of excitatory amino acids from astrocytes. J Neurosci 23(4): 1320-1328.
35. Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6(8): 595-601. doi: 10. 1038/nri1901.
36. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G, Martino G (2010) The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ 17(7): 1083-1091. doi: 10. 1038/cdd. 2009. 179.
37. Hyman MC, Petrovic-Djergovic D, Mazer SP, Pinsky DJ (2007) ENTPDase (CD39) downregulates monocyte and neutrophil MAC-1 expression. Circulation 116: 208.
38. Hyman MC, Petrovic-Djergovic D, Visovatti SH, Liao H, Yanamadala S, Bouis D, Su EJ, Lawrence DA, Broekman MJ, Marcus AJ, Pinsky DJ (2009) Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest 119(5): 1136-1149. doi: 10. 1172/JCI36433.
39. Bianco F, Ceruti S, Colombo A, Fumagalli M, Ferrari D, Pizzirani C, Matteoli M, Di Virgilio F, Abbracchio MP, Verderio C (2006) A role for P2X7 in microglial proliferation. J Neurochem 99(3): 745-758. doi: 10. 1111/j. 1471-4159. 2006. 04101. x.
40. Monif M, Reid CA, Powell KL, Smart ML, Williams DA (2009) The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. J Neurosci 29(12): 3781-3791. doi: 10. 1523/JNEUROSCI. 5512-08. 2009.
41. Verderio C, Matteoli M (2001) ATP mediates calcium signaling between astrocytes and microglial cells: modulation by IFN-gamma. J Immunol 166(10): 6383-6391.
42. Sharp AJ, Polak PE, Simonini V, Lin SX, Richardson JC, Bongarzone ER, Feinstein DL (2008) P2X7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J Neuroinflammation 5: 33. doi: 10. 1186/1742-2094-5-33.
43. Chen L, Brosnan CF (2006) Exacerbation of experimental autoimmune encephalomyelitis in P2X7R-/- mice: evidence for loss of apoptotic activity in lymphocytes. J Immunol 176(5): 3115-3126.
44. Brough D, Le Feuvre RA, Iwakura Y, Rothwell NJ (2002) Purinergic (P2X7) receptor activation of microglia induces cell death via an interleukin-1-independent mechanism. Mol Cell Neurosci 19(2): 272-280. doi: 10. 1006/mcne. 2001. 1054.
45. Alcaraz L, Baxter A, Bent J, Bowers K, Braddock M, Cladingboel D, Donald D, Fagura M, Furber M, Laurent C, Lawson M, Mortimore M, McCormick M, Roberts N, Robertson M (2003) Novel P2X7 receptor antagonists. Bioorg Med Chem Lett 13(22): 4043-4046.
46. Baxter A, Bennion C, Bent J, Boden K, Brough S, Cooper A, Kinchin E, Kindon N, McInally T, Mortimore M, Roberts B, Unitt J (2003) Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists. Bioorg Med Chem Lett 13(16): 2625-2628.
47. Friedle SA, Curet MA, Watters JJ (2010) Recent patents on novel P2X7 receptor antagonists and their potential for reducing central nervous system inflammation. Recent Pat CNS Drug Discov 5(1): 35-45.
48. 11 receptor expression by human lymphocytes: evidence for two cAMP-linked purinoceptors. Eur J Pharmacol 426(3): 157-163.
49. Schnurr M, Toy T, Shin A, Wagner M, Cebon J, Maraskovsky E (2005) Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood 105(4): 1582-1589. doi: 10. 1182/blood-2004-05-1718.
50. 11 nucleotide receptor: mutational analysis. Br J Pharmacol 155(8): 1250-1255. doi: 10. 1038/bjp. 2008. 352.
51. 11 purinergic receptor in human granulocytes. J Biol Chem 281(42): 31419-31429. doi: 10. 1074/jbc. M606625200.
52. 11 receptor. J Immunol 179(12): 8544-8553.
53. 2 nucleotide receptor-mediated responses in brain cells. Mol Neurobiol 41(2-3): 356-366. doi: 10. 1007/s12035-010-8115-7.
54. 2 receptor. J Neurochem 109(5): 1300-1310. doi: 10. 1111/j. 1471-4159. 2009. 06048. x.
55. 2 nucleotide receptor mediates UTP-induced vascular cell adhesion molecule-1 expression in coronary artery endothelial cells. J Biol Chem 278(27): 24960-24965. doi: 10. 1074/jbc. M301439200.
56. 3 receptors. Science 314(5806): 1792-1795. doi: 10. 1126/science. 1132559.
57. Junger WG (2008) Purinergic regulation of neutrophil chemotaxis. Cell Mol Life Sci 65(16): 2528-2540. doi: 10. 1007/s00018-008-8095-1.
58. 2 receptor regulates LPS-induced neutrophil transendothelial migration in vitro. Mol Immunol 47(5): 991-999. doi: 10. 1016/j. molimm. 2009. 11. 020.
59. 2 receptors induce increased MCP-1/CCL2 synthesis and release from rat alveolar and peritoneal macrophages. J Immunol 179(9): 6016-6023.
60. 6 receptors on monocytes is required for TLR1/2-induced neutrophil migration by regulating IL-8 secretion. Eur J Immunol 39(10): 2885-2894.
61. Fields RD (2011) Nonsynaptic and nonvesicular ATP release from neurons and relevance to neuron-glia signaling. Semin Cell Dev Biol 22(2): 214-219. doi: 10. 1016/j. semcdb. 2011. 02. 009.
62. 12 metabotropic receptor in adult rat brain. Neuroscience 141(3): 1171-1180. doi: 10. 1016/j. neuroscience. 2006. 05. 058.
63. 12 receptor-mediated chemotaxis of microglia. J Neurosci Res 86(7): 1511-1519. doi: 10. 1002/jnr. 21610.
64. 12 receptor protein in cortical gray matter lesions in multiple sclerosis. Cereb Cortex 20(6): 1263-1273. doi: 10. 1093/cercor/bhp193.
65. Neumann H, Kotter MR, Franklin RJ (2009) Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132(Pt 2): 288-295. doi: 10. 1093/brain/awn109.
66. Kukulski F, Ben Yebdri F, Lefebvre J, Warny M, Tessier PA, Sévigny J (2007) Extracellular nucleotides mediate LPS-induced neutrophil migration in vitro and in vivo. J Leukoc Biol 81(5): 1269-1275.
67. 6 receptors is a mediator of microglial phagocytosis. Nature 446(7139): 1091-1095. doi: 10. 1038/nature05704.
68. Ceruti S, Villa G, Genovese T, Mazzon E, Longhi R, Rosa P, Bramanti P, Cuzzocrea S, Abbracchio MP (2009) The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injury. Brain 132(Pt 8): 2206-2218. doi: 10. 1093/brain/awp147.
69. Ceruti S, Vigano F, Boda E, Ferrario S, Magni G, Boccazzi M, Rosa P, Buffo A, Abbracchio MP (2011) Expression of the new P2Y-like receptor GPR17 during oligodendrocyte precursor cell maturation regulates sensitivity to ATP-induced death. Glia 59(3): 363-378. doi: 10. 1002/glia. 21107.
70. Lecca D, Trincavelli ML, Gelosa P, Sironi L, Ciana P, Fumagalli M, Villa G, Verderio C, Grumelli C, Guerrini U, Tremoli E, Rosa P, Cuboni S, Martini C, Buffo A, Cimino M, Abbracchio MP (2008) The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One 3(10): e3579. doi: 10. 1371/journal. pone. 0003579.
71. Chen Y, Wu H, Wang S, Koito H, Li J, Ye F, Hoang J, Escobar SS, Gow A, Arnett HA, Trapp BD, Karandikar NJ, Hsieh J, Lu QR (2009) The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-intrinsic timer of myelination. Nat Neurosci 12(11): 1398-1406. doi: 10. 1038/nn. 2410.
72. Fumagalli M, Daniele S, Lecca D, Lee PR, Parravicini C, Fields RD, Rosa P, Antonucci F, Verderio C, Trincavelli ML, Bramanti P, Martini C, Abbracchio MP (2011) Phenotypic changes, signaling pathway, and functional correlates of GPR17-expressing neural precursor cells during oligodendrocyte differentiation. J Biol Chem 286(12): 10593-10604. doi: 10. 1074/jbc. M110. 162867.
73. Stone TW, Ceruti S, Abbracchio MP (2009) Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 193: 535-587. doi: 10. 1007/978-3-540-89615-9_17.
74. Linden J (2005) Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 67(5): 1385-1387. doi: 10. 1124/mol. 105. 011783.
75. Abbracchio MP, Ceruti S (2007) P1 receptors and cytokine secretion. Purinergic Signal 3(1-2): 13-25. doi: 10. 1007/s11302-006-9033-z.
76. 2A receptors. Annu Rev Immunol 22: 657-682. doi: 10. 1146/annurev. immunol. 22. 012703. 104731.
77. 2 adenosine receptors? Trends Immunol 26(6): 299-304. doi: 10. 1016/j. it. 2005. 04. 004.
78. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP (2002) Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 110(7): 993-1002.
79. Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, Colgan SP (2009) Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 113(1): 224-232. doi: 10. 1182/blood-2008-06-165746.
80. Hasko G, Pacher P, Vizi ES, Illes P (2005) Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 26(10): 511-516. doi: 10. 1016/j. tips. 2005. 08. 004.
81. 1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 24(6): 1521-1529. doi: 10. 1523/JNEUROSCI. 4271-03. 2004.
82. 1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Ann Neurol 45(5): 633-639.
83. 1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol 49(5): 650-658.
84. 1 receptors reduce release from excitatory but not inhibitory synaptic inputs onto lateral horn neurons. J Neurosci 21(16): 6308-6320.
85. 1 adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes. Glia 27(3): 275-281. doi: 10. 1002/(SICI)1098-1136(199909)27: 3& 275:: AID-GLIA9> 3. 0. CO; 2-0.
86. Gessi S, Varani K, Merighi S, Fogli E, Sacchetto V, Benini A, Leung E, Mac-Lennan S, Borea PA (2007) Adenosine and lymphocyte regulation. Purinergic Signal 3(1-2): 109-116. doi: 10. 1007/s11302-006-9042-y.
87. 2B adenosine receptor functioning by tumour necrosis factor a in human astroglial cells. J Neurochem 91(5): 1180-1190. doi: 10. 1111/j. 1471-4159. 2004. 02793. x.
88. Schwaninger M, Neher M, Viegas E, Schneider A, Spranger M (1997) Stimulation of interleukin-6 secretion and gene transcription in primary astrocytes by adenosine. J Neurochem 69(3): 1145-1150.
89. 3 receptor-induced CCL2 synthesis in cultured mouse astrocytes. Glia 46(4): 410-418. doi: 10. 1002/glia. 20016.
90. 3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cells. Neurosci Lett 396(1): 1-6. doi: 10. 1016/j. neulet. 2005. 11. 004.
91. Kukulski F, Komoszynski M (2003) Purification and characterization of NTPDase1 (ecto-apyrase) and NTPDase2 (ecto-ATPase) from porcine brain cortex synaptosomes. Eur J Biochem 270(16): 3447-3454.
92. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell'Acqua ML, Rossini PM, Battistini L, Rotzschke O, Falk K (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110(4): 1225-1232. doi: 10. 1182/blood-2006-12-064527.
93. Pulte ED, Broekman MJ, Olson KE, Drosopoulos JH, Kizer JR, Islam N, Marcus AJ (2007) CD39/NTPDase-1 activity and expression in normal leukocytes. Thromb Res 121(3): 309-317. doi: 10. 1016/j. thromres. 2007. 04. 008.
94. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC (2007) CD39 and control of cellular immune responses. Purinergic Signal 3(1-2): 171-180. doi: 10. 1007/s11302-006-9050-y.
95. Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O'Farrelly C, Tubridy N, Mills KH (2009) CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 183(11): 7602-7610. doi: 10. 4049/jimmunol. 0901881.
96. Kukulski F, Bahrami F, Ben Yebdri F, Lecka J, Martín-Satué M, Lévesque SA, Sévigny J (2011) NTPDase1 controls IL-8 production by human neutrophils. J Immunol 187(2): 644-653.
97. Lévesque SA, Kukulski F, Enjyoji K, Robson SC, Sévigny J (2010) NTPDase1 governs P2X7-dependent functions in murine macrophages. Eur J Immunol 40(5): 1473-1485. doi: 10. 1002/eji. 200939741.
98. Imai M, Goepfert C, Kaczmarek E, Robson SC (2000) CD39 modulates IL-1 release from activated endothelial cells. Biochem Biophys Res Commun 270(1): 272-278. doi: 10. 1006/bbrc. 2000. 2410.
99. Liao H, Hyman MC, Baek AE, Fukase K, Pinsky DJ (2010) cAMP/CREB-mediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression. J Biol Chem 285(19): 14791-14805. doi: 10. 1074/jbc. M110. 116905.
100. Spanevello RM, Mazzanti CM, Bagatini M, Correa M, Schmatz R, Stefanello N, Thome G, Morsch VM, Becker L, Belle L, de Oliveira L, Schetinger MR (2010) Activities of the enzymes that hydrolyze adenine nucleotides in platelets from multiple sclerosis patients. J Neurol 257(1): 24-30. doi: 10. 1007/s00415-009-5258-4.
101. Spanevello RM, Mazzanti CM, Schmatz R, Thome G, Bagatini M, Correa M, Rosa C, Stefanello N, Belle LP, Moretto MB, Oliveira L, Morsch VM, Schetinger MR (2010) The activity and expression of NTPDase is altered in lymphocytes of multiple sclerosis patients. Clin Chim Acta 411(3-4): 210-214. doi: 10. 1016/j. cca. 2009. 11. 005.
102. Airas L, Niemela J, Yegutkin G, Jalkanen S (2007) Mechanism of action of IFN-beta in the treatment of multiple sclerosis: a special reference to CD73 and adenosine. Ann N Y Acad Sci 1110: 641-648. doi: 10. 1196/annals. 1423. 067.
103. Niemela J, Ifergan I, Yegutkin GG, Jalkanen S, Prat A, Airas L (2008) IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. Eur J Immunol 38(10): 2718-2726. doi: 10. 1002/eji. 200838437.
104. Franco R, Casado V, Ciruela F, Saura C, Mallol J, Canela EI, Lluis C (1997) Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol 52(4): 283-294.
105. Vivekanandhan S, Soundararajan CC, Tripathi M, Maheshwari MC (2005) Adenosine deaminase and 5′-nucleotidase activities in peripheral blood T cells of multiple sclerosis patients. Neurochem Res 30(4): 453-456.
106. Czarnecka J, Cieslak M, Komoszynski M (2005) Application of solid phase extraction and high-performance liquid chromatography to qualitative and quantitative analysis of nucleotides and nucleosides in human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 822(1-2): 85-90. doi: 10. 1016/j. jchromb. 2005. 05. 026.